Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

388 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Tiotropium versus placebo for chronic obstructive pulmonary disease.
Karner C, Chong J, Poole P. Karner C, et al. Among authors: poole p. Cochrane Database Syst Rev. 2014 Jul 21;(7):CD009285. doi: 10.1002/14651858.CD009285.pub3. Cochrane Database Syst Rev. 2014. PMID: 25046211 Review.
However, subgroup analysis found a significant difference between the studies using a dry powder inhaler and those with a soft mist inhaler (test for subgroup differences: P = 0.01). ...
However, subgroup analysis found a significant difference between the studies using a dry powder inhaler and those with a soft mist inhaler …
Influenza vaccine for patients with chronic obstructive pulmonary disease.
Poole PJ, Chacko E, Wood-Baker RW, Cates CJ. Poole PJ, et al. Cochrane Database Syst Rev. 2000;(4):CD002733. doi: 10.1002/14651858.CD002733. Cochrane Database Syst Rev. 2000. PMID: 11034751 Updated. Review.
This difference was mainly due to the reduction in exacerbations occurring after 3 weeks (WMD -0.44, (95% CI -0.68 to -0.20, p<0.001). The number of patients experiencing late exacerbations was also significantly less (OR= 0.13, 95%CI 0.04 to 0.45, p=0.002). Ther …
This difference was mainly due to the reduction in exacerbations occurring after 3 weeks (WMD -0.44, (95% CI -0.68 to -0.20, p<0.0 …
Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease.
Poole PJ, Black PN. Poole PJ, et al. Cochrane Database Syst Rev. 2003;(2):CD001287. doi: 10.1002/14651858.CD001287. Cochrane Database Syst Rev. 2003. PMID: 12804402 Updated. Review.
Compared with placebo, there was a significant reduction in the number of exacerbations per patient with oral mucolytics (weighted mean difference (WMD) -0.066 per month, 95% confidence interval -0.077, -0.054, p<0.001). ...The number of days of disability also fell (WM …
Compared with placebo, there was a significant reduction in the number of exacerbations per patient with oral mucolytics (weighted mean diff …
Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review.
Poole PJ, Black PN. Poole PJ, et al. BMJ. 2001 May 26;322(7297):1271-4. doi: 10.1136/bmj.322.7297.1271. BMJ. 2001. PMID: 11375228 Free PMC article. Review.
RESULTS: Compared with placebo, the number of exacerbations was significantly reduced in subjects taking oral mucolytics (weighted mean difference -0.07 per month, 95% confidence interval -0.08 to -0.05, P<0.0001). ...Days of illness also fell (weighted mean difference …
RESULTS: Compared with placebo, the number of exacerbations was significantly reduced in subjects taking oral mucolytics (weighted mean diff …
Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease.
Poole PJ, Black PN. Poole PJ, et al. Cochrane Database Syst Rev. 2000;(2):CD001287. doi: 10.1002/14651858.CD001287. Cochrane Database Syst Rev. 2000. PMID: 10796634 Updated. Review.
Compared with placebo, there was a significant reduction in the number of exacerbations per patient with oral mucolytics (weighted mean difference (WMD) -0.067 per month, 95% confidence interval -0.079, -0.055, p<0.001) which is a 29% reduction. ...The number of days of …
Compared with placebo, there was a significant reduction in the number of exacerbations per patient with oral mucolytics (weighted mean diff …
Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease.
Poole PJ, Black PN. Poole PJ, et al. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD001287. doi: 10.1002/14651858.CD001287.pub2. Cochrane Database Syst Rev. 2006. PMID: 16855965 Updated. Review.
Influenza vaccine for patients with chronic obstructive pulmonary disease.
Poole PJ, Chacko E, Wood-Baker RW, Cates CJ. Poole PJ, et al. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD002733. doi: 10.1002/14651858.CD002733.pub2. Cochrane Database Syst Rev. 2006. PMID: 16437444 Updated. Review.
This was due to the reduction in "late" exacerbations occurring after three or four weeks (WMD -0.39, 95% CI -0.61 to -0.18, P = 0.0004). In Howells 1961, the number of patients experiencing late exacerbations was also significantly less (odds ratio 0.13, 95% CI 0.04 to 0. …
This was due to the reduction in "late" exacerbations occurring after three or four weeks (WMD -0.39, 95% CI -0.61 to -0.18, P = 0.00 …
Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis.
Salpeter SR, Ormiston TM, Salpeter EE, Poole PJ, Cates CJ. Salpeter SR, et al. Among authors: poole pj. Respir Med. 2003 Oct;97(10):1094-101. doi: 10.1016/s0954-6111(03)00168-9. Respir Med. 2003. PMID: 14561016
Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease.
Granger R, Walters J, Poole PJ, Lasserson TJ, Mangtani P, Cates CJ, Wood-Baker R. Granger R, et al. Among authors: poole pj. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD001390. doi: 10.1002/14651858.CD001390.pub2. Cochrane Database Syst Rev. 2006. PMID: 17054135 Updated. Review.
WITHDRAWN: Prophylactic antibiotic therapy for chronic bronchitis.
Staykova T, Black PN, Chacko EE, Poole P. Staykova T, et al. Among authors: poole p. Cochrane Database Syst Rev. 2013 Nov 29;(11):CD004105. doi: 10.1002/14651858.CD004105.pub2. Cochrane Database Syst Rev. 2013. PMID: 24293291 Review. No abstract available.
388 results
Jump to page
Feedback